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Biological fluids are commonly analyzed in clinical and forensic studies for drug 
concentration measurements. Conventional quantification procedures are always associated 
with lengthy sample pretreatment steps to eliminate the interfering compounds that potentially 
exist in complex biological matrices. The objective of this study was to address these 
problems employing solid-phase microextraction (SPME) technique. Antibodies (Abs) were 
employed to serve as an extremely specific extraction phase for direct extraction of analytes 
from untreated biological matrices based on their exquisite selectivity for antigens (Ags). 
Much of the research was focused on selecting the most appropriate antibody (Ab) for a 
particular application based on evaluation of characteristics of various types of Abs obtained 
from four suppliers. Abs’ binding characteristics were evaluated before and after 
immobilization in terms of affinity, valence, homogeneity, capacity and cross-reactivity for 
three benzodiazepines. The performance of immunoaffinity probes of the same type provided 
by different suppliers was found to be comparable. Finally, the probes’ utility for extraction of 
benzodiazepines from plasma samples was evaluated.  
The limit of detection of the method developed in this work was 0.01 ng/mL with upper 
limits of quantification of 0.5 ng/mL in buffer and 2 ng/mL in plasma. The method’s precision 
was 12% for extraction from buffer and less than 10% for extraction from plasma. With limits 
of detection similar to the current state-of-the-art methods available for quantification of drugs 
in biological matrices, the method presented in this thesis was found advantageous compared 
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Chapter 1 Introduction 
Biological fluids are frequently analyzed in pharmaceutical studies for drug 
concentration measurements. These measurements are often used in clinical medicine to 
ensure appropriate therapeutic levels of drugs while minimizing the occurrence of toxicity.  
Biological samples are considered complex matrices due to the presence of a variety of 
species such as proteins, salts and organic compounds. These compounds, which often exist at 
higher concentrations than analytes, can interfere with analyte concentration measurements. 
Therefore, determination of drug levels in biological samples, such as plasma or urine, cannot 
be performed directly.  
Elimination of interfering compounds from the matrix is an inevitable step in the 
course of analyzing biological fluids and is commonly performed in a series of steps, referred 
to as sample preparation. Preparation of a pure, concentrated sample requires several steps 
during which the risks of operator error, sample loss and/or sample contamination increase 
with each additional step. As a result, in drug quantification procedures, a sample preparation 
method with a minimal number of steps is aimed for extraction and isolation of the analyte of 
interest. 
Solid-phase microextraction (SPME), invented in the late 1980s by Belardi and 
Pawliszyn
1
, has been exploited in a wide range of applications as a powerful sampling and 
sample preparation technique.
2
 While sample preparation is generally laborious and time 
consuming, SPME integrates extraction, concentration and clean-up into a single, solvent-free 
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step with high sensitivity.
3,4
 Therefore the present work focused on exploiting the SPME 
technique for accurate quantification of drugs in biological samples to avoid the time and labor 
intensive sample preparation steps frequently conducted in conventional pharmaceutical 
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1.1 Drug analysis by SPME 
 The SPME technique invovles exposing a small amount of extraction phase, coated 
onto a solid support, to the sample matrix for a defined period of time. Partitioning of analyte 
molecules onto the extraction phase occurs during the extraction time, following which the 
SPME device is removed from the sample. The extracted analytes are then desorbed from the 
extraction phase and introduced to an analytical instrument for separation, identification and 
quantification.
4
 Quantification in SPME is based on the fact that the amount of extracted 
analyte is proportional to the initial concentration of analyte in the sample matrix.  
SPME was primarily developed for extraction of volatile organic compounds from 
environmental samples. Consequently, commercially available SPME extraction phases are 
generally suitable for extraction of volatile compounds with relatively low polarity, which are 
typically analyzed using gas chromatography (GC).
5
 Analysis of pharmaceuticals in biological 
matrices, on the other hand, is often performed using liquid chromatography (LC) due to the 
analytes’ higher polarity, lower volatility and in some cases, thermal instability. The only 
commercialized extraction phase that is appropriate for LC applications is 
Carbowax/templated resin (CW/TPR), which is not always suitable for drug quantification in 
biological matrices.
5
 Yet, commercial SPME fibers have been used in several studies mostly 
in conjunction with GC devices for drug analysis.
 6-14
 
Commercial SPME fibers have been employed extensively for drug analysis in 
toxicological cases of accidental or suicidal drug overdoses, rather than therapeutic drug 
monitoring studies.
10
 This is due to the limit of quantification associated with commercial 
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SPME fibers which is often higher than therapeutic levels of drugs. In one approach, 
benzodiazepines were analyzed in blood with high sensitivity using a polypyrrole (PPY) 
extraction phase, which had lower detection limits than analyte concentration.
5
 However, 
many drugs are commonly present at much lower concentrations than benzodiazepines. Thus, 
the search for extraction phases with higher sensitivity continues.  
Furthermore, a minimum of one sample preparation step was shown to be essential in 
almost all drug analysis studies where currently available SPME fibers were used.
6-14
 In the 
case of extraction from plasma samples in particular, deproteinization was found to be 




Nevertheless, SPME is chosen over other conventional sample preparation methods 
due to its potential to eliminate all sample pretreatment steps by combining several steps into 
one step. Therefore, the aim of the present research was to design a SPME probe for direct 
extraction of drugs from biological matrices.  
Adsorptive extraction phases have generally been employed in drug analysis. The 
amount of drug extracted is directly dependent on the affinity of the analytes to the adsorption 
sites as well as the amount of sorbent, and the analyte’s concentration in the sample. Thus, 
selection of an appropriate extraction phase is the primary step in designing an SPME probe 
for any particular application.  
As mentioned previously, none of the commercially available SPME probes are ideally 
suited for specific quantification of pharmaceuticals from complex matrices. The extraction 
phases developed for this purpose, such as PPY,
5
 are general sorbents for which the affinity 
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coefficients of a broad range of compounds are generally understood to differ by less than 
three orders of magnitude.
15
 Employing such sorbents, that extract a wide range of analytes 
with moderate affinities, is associated with co-extraction of competing compounds. Indeed, 
when analyzing real samples where trace levels of analytes exist along with interfering 
compounds at considerably higher concentrations, the issue of co-extraction becomes a major 
problem. Due to the fixed extraction capacity of the fibers, the compounds with lower 
affinities and higher concentrations compete with the analytes of interest for the sites on the 
extraction phase. In such cases, displacement of analytes by interfering compounds is likely to 
occur. This problem can be avoided by exploiting highly selective sorbents to extract a few 
structurally similar drugs with high affinity. Antibodies (Abs) have been chosen as sorbents in 












The primary step in developing Ab-based sorbents is identification of Abs that can 
recognize one or a group of target analytes. For each application, the proper Ab is selected 
based on its characteristics, which determine the sensitivity and selectivity of the sorbent.   
1.2.1 Antibody structure and classification 
Abs, also referred to as immunoglobulins (Igs), are glycoproteins that belong to the 
“globulin” family of proteins in serum. The immune system of living organisms produces Abs 
in response to invasion by foreign molecules. Foreign substances capable of evoking such 
immune response are called immunogens. The presence of an immunogen activates a chain of 
reactions that ultimately triggers production of Abs by white blood cells (lymphocytes). The 
terms “antigen” and “immunogen” are often used interchangeably; however, it should be 
noted that, not all antigens can evoke an immune response.
16
  
Although Abs carryout various functions in the immune response, all Abs exist as Y-
shaped units consisting of four chains of polypeptides. The basic structure of each Y-shaped 
unit consists of two identical “heavy” chains (~ 50 kDa each) that are coupled with two 
identical “light” chains (~ 25kDa each) by a variable number of disulfide bonds. The resulting 
150 kDa Ab has a central axis of symmetry that splits the Ab molecule into two identical 
halves.
16-18
 The sequence of amino acids at the “tail” of the “Y” structure, the Fc fragment, 
determines the major class the Ab belongs to while the amino acid composition at the two tips 






Figure 1: Structure of Immunoglobulin G showing Fab 







There are five major classes of Abs in higher mammals: IgA, IgD, IgE, IgG and IgM. 
These classes differ from each other in the number of Y units they have as well as the amino 
acid sequences in the heavy chain of their Fc fragments. In the development of immuno-based 
sample preparation techniques, Immunoglobulin G (IgG) is chosen to be used in almost all 
cases. This is primarily due to the fact that IgG is the most abundant class of Igs in serum 
following immunization; although other reasons include its stability during purification 
processes, its higher affinity for Ags as well as the availability of a wide range of commercial 
purification kits specifically for IgG. For all of these reasons, IgG was also chosen to be use in 
the present study.  
Ags are also classified based on their binding properties. The sites of Ags and 
immunogens that interact with complementary sites on Abs are called epitopes (Figure1). 
Pharmaceuticals which are the target analyte in pharmaceutical studies each have a single 
epitope to bind to an Ab. Such Ags are also called haptens (Hs).  Similar to other molecules 
with molecular weights smaller than 1000 Da, Hs are inherently unable to evoke an immune 
response. Thus, anti-hapten Abs are commonly produced by conjugating the desired hapten to 
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a carrier protein such as bovine serum albumin (BSA). To avoid confusion in the text, I have 
used Ag instead of H.  
1.2.2 Antibody characteristics 
In general, Abs are characterized based on three major qualities: specificity, cross-
reactivity and affinity. Each one of these characteristics is explained in this section. 
Specificity is defined as the ability of an Ab to bind only to the analyte of interest.
20
 
Since only a limited number of Abs can be immobilized on the sorbent support, specificity of 
the Ab batches that will be immobilized plays an important role in the development of 
immunoaffinity adsorbents. As mentioned previously, the chance of co-extraction of 
interfering compounds is significant when dealing with complex matrices. The possibility of 
co-extraction of other compounds increases if the Abs, which in this work, serve as the 
extraction phase, are not specific to the analyte. 
Cross-reactivity is the tendency of Abs to bind to Ags other than target analyte(s). 
Although Abs have typically been employed in analytical techniques because of their unique 
specificity for their Ags, molecules with closely related structures (e.g. drug metabolites) are 
likely to cross-react. There is also a chance for cross-reaction with molecules that have 
dissimilar structures but are present in the sample at high concentrations. Cross-reactivity is 
often described as the amount of cross-reactant that displaces the target analyte by 50%. Some 
antibody-producing companies measure cross-reactivity in relation to relative affinity, 
meaning that 100% cross-reactivity is assigned to the Ag for which the Ab has the highest 




Affinity of an Ab is defined as the association constant of the Ab complex with an Ag. 
Abs are known for identification of their specific Ags and subsequent formation of a stable 
complex with those Ags. The interaction of an Ab with its selective Ag is called the “primary 
interaction”. This is a fairly rapid interaction that results in equilibrium between the free and 
the antibody-bound antigen.The general binding procedure is described by the following 
equations: 
Ab + Ag         Ab - Ag     (1.1)         
    Affinity = Ka = [Ab - Ag] / [Ab] [Ag]  (1.2) 
where Ab-Ag is the antibody-antigen complex and Ka, generally referred to as “affinity” of an 
antibody for a specific antigen, is the association constant for binding of the Ab with the Ag. 
The square brackets correspond to molar concentration or surface concentration of each 
species at equilibrium.  
The binding forces involved in the interaction of Ab and Ag include hydrogen bonding 
and hydrophobic forces along with coulombic and van der Waals interactions. Although these 
forces are relatively weak, complementarity of Ag and Ab binding sites takes place at a 








 Such large 
values of the association constant leads to the conclusion that the Ab-Ag complex is formed 
even when both Ab and Ag are present at very low concentrations. It is also expected that the 
dissociation of the Ab-Ag complex can only be achieved under extreme conditions. 
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1.2.3 Evaluation of affinity in solution 
The evaluation of binding properties between proteins and small molecules was 
initially conducted by George Scatchard in 1949.
22
 Consequently, current evaluation of an 
Ab’s affinity for an Ag is commonly performed by Scatchard analysis. This method is a 
thermodynamic approach that is applied to the equilibrium between Ab and Ag in solution.  
Experimental evaluation of Ab affinity is performed by incubating the Ab at constant 
concentration with an Ag at varying concentrations. To estimate Ab affinity, two assumptions 
are made: first, that both reactants, Ab and Ag, have to be pure and in solution and second, 
that the reactants should be homogenous with regard to the Ag’s epitopes and the Ab’s 
complementary binding sites.
23 
Both assumptions can be satisfied for the Ag if it is a hapten. 
However, as discussed in the next section, Abs that are naturally produced in serum are 
heterogeneous both in structure and affinity. Purification of Abs helps in getting closer to the 
ideal situation.  
Estimation of affinity is performed based on Equation 1.2. In this equation, K is to be 
identified. However, all other components in this equation are also unknown. To solve the 
equation for K, equation 1.3 is employed: 
    [Ab] = (Ab)t – [Ab-Ag]                                               (1.3) 
 
where [Ab] is the concentration of free Ab sites, [Ab-Ag] represents the concentration of bound 
Ag or occupied Ab binding sites at equilibrium and (Ab)t represents the total concentration of 




Equation 1.4 is used to determine (Ab)t as follows:  
     (Ab)t = n (Ab)                                                (1.4) 
where n represents Ab valence, defined as the number of binding sites for each Ab molecule, 
and (Ab) represents molar concentration of total Ab in sample. In experimental determination 
of antibody affinity, the total concentration of antibody shown as (Ab) is known.  
 
Substituting Equation 1.3 and Equation 1.4 in Equation 1.2 results in the following equation: 








=     (1.5) 
which is changed into Equation 1.6 following rearrangement: 
  









      (1.6) 
   
Solving Equation 1.5 for [Ag] and substituting it in the left side of Equation 1.6 leads to 
Equation 1.7 after rearrangements: 




















is the number of moles of Ag bound per mole of Ab. To simplify 
Equation 1.7, this term is shown by “r” in Equation 1.8: 










Equation 1.8 is the general Scatchard equation for an n-valent Ab. As can be seen from the 
Scatchard equation, in an ideal situation where both assumptions are true, a plot of 
][Ag
r
versus r results in a line with a negative slope (K), which is the affinity of the Ab, and an 
x-intercept (n) which is the Ab’s valence (Figure 2).  
 
 
Figure 2: Scatchard plot of 





 For an anti-hapten Ab with 2 binding sites per Ab molecule (such as IgG whose 
valence is 2), the Scatchard equation can be employed to calculate the affinity at the time 
when half of the Ab sites are bound ( 1=r ). Substituting the values for n and r in Scatchard 





1.2.4 Evaluation of affinity on solid surfaces 
The affinity of immobilized Abs is not estimated with Scatchard analysis. Since the 
number of immobilized Abs is limited by the space available on the immobilization surface, 
other techniques must be employed to accurately estimate Ab affinity. 
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As Ab-coated surfaces have defined sites to which Ags can be bound, it is expected that 
an Ab-coated surface acts in an adsorptive fashion. Therefore, higher concentrations of Ag 
lead to saturation of the Ab-coated surface. For this reason, an adsorption isotherm, which 
relates the concentration of Ab-Ag at equilibrium to the concentration of Ag in the sample, can 
be used to model the binding of an Ag to an Ab-coated surface.  
The Langmuir Adsorption Isotherm has been commonly used to model such binding. 
Equation 1.6 is a form of Langmuir Adsorption Isotherm. This equation is a hyperbola, which 
is the typical saturation function (Figure 3). At low Ag concentrations, more Ag is bound 
when more is added to the sample. At high concentrations of Ag, saturation occurs as [Ab-Ag] 





Figure 3: Graphical demonstration 





Since estimation of affinity from a non-linear function is complicated, the reciprocal of 
the Langmuir Adsorption Isotherm, which is a linear transform of the binding isotherm, has 
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   (1.9) 
where n(Ab) is equal to total binding sites of Ab immobilized on the surface. The maximum 
amount of Ab’s active sites is the capacity of the adsorption surface and is shown with b in the 









         (1.10)
 23
 
where K represents Ab affinity and n represents the capacity of the adsorption surface, defined 
as the maximum amount of Ab’s active sites. 
As can be seen from Equation 1.10, both affinity and capacity of the immobilized Ab 
can be obtained from the reciprocal Langmuir plot (Figure 4). 
 
 
Figure 4: Reciprocal Langmuir plot 





Similar to the Scatchard plot, the reciprocal Langmuir plot is obtained based on 
assumptions for homogeneity and purity of Abs. Due to the fact that Ab heterogeneity 
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increases upon immobilization, the reciprocal Langmuir plot often deviates from linearity. The 
deviation exists even when purified Abs are employed. This is due to the presence of range of 
affinities within the population of naturally produced Abs. The distribution of affinities in an 










=−                         (1.11) 
 The Sips equation has been developed based on a model in which the Gaussian 
distribution function describes the distribution of Ab affinities. In this model, K  is the average 
affinity and a , which is related to the width of the affinity distribution, is the heterogeneity 
index. Based on Sips equation, when a  is equal to 1, a single value for K  is obtained, 
demonstrating that Abs are homogeneous. The more heterogeneous the Ab population is, the 
smaller the value of a  will be, which results in a wider distribution of affinities.  
The Sips equation is frequently used in logarithmic form to produce a linear equation. 
The logarithmic form of the Sips equation is obtained by rearrangement of Equation 1.11 as 
follows: 
aa AgKbAgKAgAbAgAb ])[(])[]([][ =−+−              (1.12) 
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 is plotted versus ]log[Ag , a straight line with slope equal to 
the index of heterogeneity is obtained (Figure 5).  
 
 
Figure 5: Logarithmic form of 




Similar to Scatchard analysis, for a divalent anti-hapten Ab, K  can be determined from 
the logarithmic of the Sips equation at 50% Ab saturation. For anti-hapten IgG, when half of 













1.2.5 Antibody types 
Two types of Ab have been produced to date: polyclonal antibodies (PAbs) and 
monoclonal antibodies (MAbs). Although both types have been successfully employed in 
immunoaffinity sample preparation methods, there are advantages and disadvantages 
associated with each in terms of their binding characteristics, the procedures used for their 
preparation, and their applications. It has been found that the dissimilarity in their production 
processes is the root of the dissimilarity in their characteristics. However, both types have 
been successfully employed in immunoaffinity sample preparation methods. Since evaluation 
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of Ab characteristics is an essential part of developing any immunoaffinity method, the 
generation of both types of Ab is expressed in this section.  
PAbs are the natural products of conventional immunization in living species. During 
the immunization process for commercial scale production of PAbs, a suspension of the 
specific immunogen is injected several times into a suitable animal, such as a sheep, horse, or 
goat.
18
 Bleeding is performed at the peak of Ab production, which is determined 
experimentally. As mentioned before, drugs have to be bound to a carrier protein before being 
used as immunogens.  
Upon immunization, a wide range of B-cell lymphocyte clones are activated which 
causes a series of reactions, ultimately resulting in the production of Abs by the B-cells.
24
 
Each immunogen has various epitopes against which Abs are produced. These Abs are 
secreted in the blood where they are mixed with the Abs produced against other Ags present in 
the organism.
16,24
 The mixture of various Abs is called PAbs. As is apparent from the name, 
more than one clone of cells is responsible for the production of PAbs. 
PAbs are a heterogeneous population of Abs with a range of affinities and 
specificities.
25
 In fact, it has been reported that only 15% of polyclonal IgG is specific.
26
 This 
is mainly due to the production of Abs against various epitopes and the presence of Abs 
against other Ags in the living system. However, Abs produced against a single epitope are 
still heterogeneous with regard to their affinity and specificity.
25
  
Despite their heterogeneity, PAbs have been exploited in various research fields and 
clinical studies with great success.
25
 Nevertheless, their usage is limited to assays for which 
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Abs with high specificity and consistent quality are not crucial. In cases where a homogeneous 
population of Abs with unique specificity is desired, MAbs are the better choice.  
Since their introduction by Köhler and Milstein
27
 in 1975, MAbs have been 
extensively employed in immunoaffinity assays. MAbs are produced in vitro from a single B-
cell clone, which means they are a homogeneous population of Abs with desired specificity. 
The challenge of producing homogenous Abs from an isolated B-cell clone arises from the 
fact that B cells do not survive in cell culture for more than a few days of their isolation.
18, 28
 
Köhler and Milstein overcame the problem by fusing isolated B-cells with immortal cancerous 
cells.
27
 Such B-cells, are able to generate identical Abs with equal affinity for a single epitope 
continuously. 
The production procedure for MAbs begins with immunization of an animal, typically 
a mouse. This step follows the same principles governing PAb preparation.
18
 The B-cells that 
are responsible for production of Abs are then isolated from the animal’s spleen and fused to 
malignant plasma cells (also called myeloma cells). Hybrid cells, also known as 
“hybridomas”, are produced upon culturing the fused cells.
16
 The resulting hybridomas 
combine the properties of both B-cells and immortal malignant cells; such that they are 
capable of continuous production of consistent Abs for years while cultured in a tissue 
medium.
28
 During screening, hybridomas that generate the specific Ab of interest are 
identified and isolated from the non-specific hybridomas. Various populations of fused B-cells 
that existed in the original clone are then separated and re-cloned. Following the re-cloning 
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step, the binding characteristics of the pre-selected hybridoma is evaluated. Once the desired 
hybridoma is identified, a MAb will be produced in large scale.
28
 
1.2.6 Antibody selection  
During the course of development of an assay based on Abs, the particular application 
of the assay determines the most suitable type of Ab. Several factors including the level of 
specificity and the degree of affinity desired for that application are to be considered when 
selecting a type of Ab. In this section, the two different types of Abs are compared with regard 
to different aspects that are generally considered in designing an assay. 
As discussed previously, PAbs are heterogeneous, which means they consist of 
different classes of Igs. Therefore, lengthy purification procedures are required to isolate a 
specific class such as IgG which is the most favorable class in analytical assays.
29
 
Furthermore, due to its heterogeneity,   a PAb mixture reacts with the epitopes on an Ag with a 
wide range of affinities.
29
 To avoid production of a diverse population of irrelevant Abs, 
specific conditions need to be met with regard to their production. Indeed, aseptic areas must 
be available for housing immunized animals and, although they may not be accessible in some 
cases (e.g., for newly developed drugs), highly purified Ags must be used for immunization.
29
 
The limited supply of PAbs is another disadvantage associated with them, making 
them irreproducible. Using different animals or bleeding the same animal at different times 
can result in significant batch to batch variation.
28
 However, in spite of all their disadvantages, 
if the purified Ag is available, PAbs can be easily generated at relatively low cost.  
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The disadvantages of PAbs are eliminated for MAbs due to their production procedure. 
A batch of MAbs contains a specific Ab of a defined class (generally IgG) with high affinity 
towards a single epitope. Continuous culture of hybridomas allows unlimited production of 
consistent MAbs which are thus considered reproducible.
30
 Furthermore, this procedure 
eliminates the need to use animals for bulk production. As a result, the number of animals 
used for MAb production is drastically reduced, in comparison with PAbs.
26
 Finally, since a 
specific hybridoma is selected for production of a specific MAb based on its binding 
characteristics, highly purified Ags are not necessarily required for their production.
31
  
There are also some disadvantages associated with MAbs. Chiefly, their production is 
laborious and time-consuming compared to PAbs, they are less available compared to the wide 











1.3 Immunoaffinity sample preparation techniques 
Immuno-based sample preparation techniques are becoming increasingly popular in the 
analytical community. These techniques are based on molecular recognition and employ 
biological tools, such as Abs, for selective extraction of analytes. The interest in using Abs for 
sample preparation when dealing with complex matrices is due to their exquisite selectivity 
and high affinity for their respective Ags. Over the last decade, Abs have been utilized 
successfully in various forms including chromatography column packings,
32-35





    
Immunoaffinity chromatography (IAC) is a term for any chromatographic method with 
Abs or Ab-related compounds bound to the stationary phase. The first reported use of IAC 
dates back to 1951 when Campbell et al. employed an immobilized Ag column for purification 
of an Ab.
40
 Since its introduction, numerous IAC methods have been developed for separation 
of large molecules, such as antibodies, hormones, receptors and enzymes as well as smaller 
molecules including pesticides and drugs.
41-45
  
In the IAC technique, Abs or Ab-related compounds that are suited for any particular 
application are immobilized to a support to serve as the stationary phase. Considerations for 
selection of Ab type and immobilization method is discussed in detail in sections 1.2.6 and 
2.5, respectively. The two types of supports typically employed for IAC are low-performance 
supports, which can be used under gravity flow or slight vacuum, and higher efficiency 
supports, which can be exploited as high-performance liquid chromatography (HPLC) 
columns. Carbohydrate-related materials (e.g. agarose) or synthetic organic supports (e.g. 
acrylamide polymers) are generally low-performance supports. These materials are relatively 
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simple and inexpensive and have been used particularly in off-line immunoextraction 
methods. However, due to their slow rate of mass transfer and instability at high pressures and 
flow rates, more rigid materials such as derivatized silica are employed as supports for high-
performance Immunoaffinity chromatography (HPIAC). These materials, which are 
mechanically stable, can be used with standard HPLC equipment, thus improving the speed 
and precision of analytical applications of IAC. 
Once Abs are immobilized on the appropriate support, samples are applied to the IAC 
column. Ags are then allowed to bind to immobilized Abs over a certain period of time. 
During this time, equilibrium is established between the unbound molecules (Abs and Ags) 
and antibody antigen complex. Interfering compounds present in complex matrices are 
removed by performing a washing step after equilibration time which eliminates unbound 
compounds from the column.   
As mentioned in the previous section, under physiological conditions, Ka is typically 




 L/mol, which indicates very strong binding between analytes and 
immunoaffinity supports. Therefore, elution of analytes is performed by employing eluents 
that can change the IAC column conditions by decreasing the effective Ka value. An 
appropriate elution buffer is chosen based on its ability to elute the analyte as fast as possible 
without imposing any irreversible damage to the immobilized Ab. Buffers with extreme pH 
values, chaotropic agents (e.g. sodium iodide), denaturing agents (such as guanidinium) and 
organic modifiers, have been used as elution buffers. However, the proper elution buffer is 
determined for each case experimentally. 
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Following elution of analytes from the immunoaffinity column, the column is typically 
regenerated and stored in proper buffer for further use. 
Immunoaffinity SPE is a form of IAC. The so-called immunosorbents (ISs) are 
prepared by linking Abs to a solid support, which is then packed into an SPE cartridge. Both 
low-performance and high-performance supports have been used in preparation of ISs. 
Following preparation of an immunoaffainity SPE cartridge, the same steps are followed as in 
the IAC. 
In recent years, immunochemical methods have gained the interest of biosensor 
technology, which has resulted in the development of immunosensors. The additional 
advantage of immunosensors over other immuno-based sample preparation methods is that 
immunosensors combine specific extraction of analytes with direct detection. Since both 
isolation and detection of analytes happen at the surface of the sensor, the support for 
immobilization of Abs is different from the supports regularly used in immunoaffinity sample 
preparation methods. An immunosensor’s support is chosen based on the method of detection 
and can be varied from synthetic polymers (such as polypyrrole) to inert metallic electrodes 
(such as gold electrodes).
38 
While immunosensors have been successfully employed for 
separation and detection of analytes of interest in complex matrices, research continues, 
focusing on improving immobilization techniques for the sensors.
 39
      
The first attempt at the development of immunoaffinity solid phase microextraction 
was reported in 2001.
46
 Theophylline, a drug used in treatment of respiratory diseases, was 
determined in serum samples using anti- theophylline Abs immobilized to glass rods and 
radioisotope detection. The technique has been further improved by purification of Abs into 
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drug-specific fractions and optimization of the immobilization procedure in recent work 
conducted by H. Lord et al.
47
 The performance of the Immunoaffinity SPME glass rods have 
been demonstrated for determination of sub ng/mL concentrations of 7-aminoflunitrazepam, a 
metabolite of the club drug , flunitrazepam, in human urine samples.
48
 This work is a 
continuation of the development of the immunoaffinty SPME probes that was initiated by H. 



















1.4 Thesis objective 
The primary goal of the research discussed in this thesis was to overcome the 
limitations of SPME in monitoring trace levels of pharmaceuticals in biological fluids by 
exploiting the selective recognition and binding properties of Abs for quantification of drugs. 
This goal was achieved by extending the development of immunoaffinity SPME probes that 
had been initiated by H. Lord et al.
47, 48
  
The research was focused on two main areas; the development of a broadly applicable 
technique for extraction of drugs from biological fluids based on immunoaffinity SPME, and 
the demonstration of the technique’s application to plasma. The former objective was achieved 
by employing both types of Abs (PAb and MAb) from four different suppliers. Characteristics 
of all Abs were carefully evaluated in solution and when immobilized on silica-based support. 
Especial attention was given to the study of cross-reactivity of Abs for drugs within the same 
class, which led to interesting results. In the second phase of the research, the results for 
extraction of diazepam and its two major metabolites from plasma using all types of the 
immunoaffinity SPME probes were demonstrated. 
It should be noted that while H. Lord et al. have successfully demonstrated the utility 
of immunoaffinity SPME probes for analysis of trace levels of benzodiazepines, their work 
was mainly focused on the investigation of the new device. The aim of the current research 
was to demonstrate the device’s utility as a broadly applicable tool that can be employed with 
Abs produced in different species and by various companies. The final purpose of this 
research was to demonstrate the probes performance in plasma, the most analyzed biological 
fluid in pharmaceutical and toxicological studies. 
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Chapter 2 Materials and methods 
In this chapter, specifications of materials used for the development of immunoaffinity 
SPME probes are outlined. In addition, the methods employed for purification of Abs, 
immobilization of Abs on to solid supports and the design of experiments performed for the 
current research are expressed in the following sections. The methods for purification and 
immobilization of Abs as well as the experimental design for affinity test of Abs prior to 
immobilization are very similar to those employed by H. Lord et al. These methods are briefly 
described in this chapter; further details can be found in publications by H. Lord et al.
47,48















Anti-benzodiazepine Abs were obtained from four suppliers: Biotrend Chemikalien 
GmbH (Köln, Germany), Cortex Biochem, Inc., (San Leandro, CA, USA), Fitzgerald 
Industries International, Inc. (Concord, MA, USA) and United States Biological (Swampscott, 
MA, USA). For the sake of simplicity, short forms of the suppliers’ names are used throughout 
the text.  
Two types of PAbs were obtained from Cortex with different cross-reactivities for 
various benzodiazepines. One batch was indicated by the supplier to be cross-reactive towards 
all benzodiazepines and the other was specified as oxazepam-specific. All Abs supplied from 
other companies were described by the suppliers as cross-reactive towards benzodiazepines. 
PAbs and MAbs were raised in sheep and mice, respectively. Oxazepam was coupled to a 
carrier protein (bovine -globulin (BGG), keyhole
 
limpet hemocyanin (KLH) or bovine serum 
albumin (BSA) and used as the immunogen for preparation of Abs obtained from all 
companies except for Biotrend Chemikalien GmbH. All batches of MAbs were purified for 
IgG and supplied in Phosphate Buffered Saline (PBS) with pH ranging from 7.0 to 7.2. 
Sodium azide was also added to the purified Abs as a preservative. The MAb obtained from 
US Biological contained glycerol (in the amount of 40%) in addition to PBS. With exception 
of the Fitzgerald PAb, which was supplied in the form of purified IGg, PAbs were supplied as 
neat serum without any preservatives. All batches of PAbs, not purified for IgG by the 
supplier or containing reagents other than PBS and sodium azide were purified according to 
the procedure described in the next section. 
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Generic IgG was obtained from Jackson ImmunoResearch Laboratories Inc. (West 
Grove, PA, USA) in the form of purified IgG in phosphate buffer. According to the supplier, 
generic IgG was separated from non-immunized sheep serum. 
Human plasma was obtained from US Biological. As indicated by the supplier, the 
plasma had been obtained from healthy male donors and was mixed with the appropriate 
amount of potassium ethylenediaminetetraaceticacid to prevent coagulation of plasma 
proteins.  
Benzodiazepines (diazepam, nordiazepam, oxazepam and lorazepam) were obtained 
from Cerilliant (Round Rock, TX, USA) in the form of 1 mg/mL certified standards in 
methanol or acetonitrile. Intermediate standards were prepared by dilution of the primary 
standards with methanol. Final standards to be used for extraction were prepared on the day of 
experimentation by dilution of intermediate standards with PBS.  
PBS was prepared in-house with sodium chloride (0.1 M), sodium phosphate dibasic 
(11.4 mM), potasium chloride (2.7 mM) and potassium phosphate monobasic (1.8 mM). The 
pH was adjusted to 7.4 with 5M NaOH. PBS was prepared fresh every month and stored at     
4 
o
C. A Corning pH meter (model 220) was employed along with Corning combination 
electrode with calomel reference electrode from Fischer Scientific (Ottawa, ON, Canada). 
Purification of IgG from other proteins in serum was performed using a Protein G 
affinity column and reagents supplied in a “ImmunoPure® (G) IgG Purification Kit” by Pierce 
Biotechnology (Rockford, IL, USA). Another affinity kit from Pierce Biotechnology 
(Pharmalink™ Immobilization Kit) was employed for affinity purification of polyclonal IgG. 
The purification procedures are described in the following sections. 
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The immobilization reagents including aminopropyltriethoxysilane (APTES) at 99% 
purity and glutaraldehyde grade II (25% aqueous solution) were purchased from Sigma-
Aldrich (Oakville, ON, Canada). Abs were immobilized on borosilicate glass rods (diameter: 4 
mm, length: 10 cm) that were obtained from the University of Waterloo glass blower. 
All other chemicals were ACS grade or higher. HPLC-grade solvents and nano-pure 
water were used for preparation of buffers and mobile phases. The nano-pure water was 
collected from a water deionization system from Barnstead (Dubuque, IA, USA) at 18MΩ.  
Centrifugal devices were obtained from Millipore Corporation (Bedford, MA, USA). 
Amicon Ultra-4 centrifugal filter units (volume: 4 mL) with molecular weight cut off 
(MWCO) of 30,000 and 10,000 Da were employed for concentration and buffer exchange of 
Abs. Ultrafree-MC centrifugal filter units (volume: 0.4 mL) with MWCO of 30,000 Da were 
used in affinity testing of Abs in solution. 
A magnetic stirrer, 96-well plates and vials used for extraction were obtained from 
VWR Scientific (Mississauga, ON, Canada). The 96-well plate dryer was constructed at the 
University of Waterloo Science Shops from stainless steel and standard “yellow” pipette tips 
(1-200 µL) from VWR. The pipette tips could be replaced if contaminated.  
Samples were agitated during extraction and desorption processes using a Jeiotech SK-
300 rotary shaker from Rose Scientific (Edmonton, AB, Canada). The ultraviolet 
spectrophotometer used for measuring protein concentration at 280 nm is a Spectronic 
Biomate 3 purchased from Thermo Scientific (Nepean, ON, Canada). An Eppendorf Repeater 




Linear regression analysis was performed using Microsoft Excel 2000. Data for 
calibration of immunoaffinity SPME probes, which required non-linear regression, were fit to 









=  using SigmaPlot software 
(version 9.0). In this equation, y  is the amount of Ag  extracted (pg), x  is Ag  concentration at 
equilibrium,a is the heterogeneity index, b is the probe’s capacity and K  is the affinity of 
immobilized Abs.  
2.1.1 Model drug selection 
Four drugs, all classified as benzodiazepines, were selected for this research. 
Measurement of benzodiazepine concentrations in biological fluids has been the topic of 
numerous studies as drugs from this family are frequently prescribed as tranquilizers, 
anticonvulsants and sleep inducers. They have also been studied extensively in toxicological 
cases since they are often abused in large doses by illicit drug users.
49
 As a result, their 
physiochemical properties and pharmacokinetics in a variety of animals are well defined. 
Having a liquid chromatography-tandem mass spectrometry (LC/MS/MS) system available for 
this work, the use of benzodiazepines in this research was additionally advantageous as they 
show good sensitivity in mass spectrometry (MS) analysis, and have been widely analyzed by 
chromatographic techniques coupled with MS.
49
 Finally, benzodiazepines and their 
corresponding Abs are commercially available, which made benzodiazepines suitable as 
model drugs for the current work. 
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Diazepam, its two major metabolites (nordiazepam and oxazepam), and lorazepam 
were the drugs from the benzodiazepines’ class chosen for these studies. Their chemical 
structures are shown in Figure 6. 
 
Diazepam (mw: 284.7)  Nordiazepam (mw: 270.7)   Oxazepam (mw: 286.7)    Lorazepam (mw: 321.2) 
Figure 6: Chemical structures and molecular weights of the target drugs used in the studies   
  
Diazepam, nordiazepam and oxazepam are closely related in structure and can co-exist 
in plasma. Therefore, studying specificity and cross-reactivity of the SPME probes for the 
parent drug and its significant primary metabolites was seen as important for the purpose of 
this research. 
Lorazepam, which is a frequently prescribed benzodiazepine, was added to samples as 
the internal standard. Although it is from the same class of drugs, its structure is different from 
the other three in a way that unless added to the samples, there is no way for it to 
spontaneously arise in biological samples from diazepam metabolism. Conveniently, it also 
has good chromatographic properties for the liquid chromatography/tandem mass 
spectrometry (LC/MS/MS) method employed in the current work.  
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2.2 IgG purification 
Serum contains various proteins (such as albumin) as well as all classes of Abs. All 
batches of Abs that were supplied either in the form of serum or in solutions other than PBS 
buffer were treated for isolating IgG and transferred to a solution of PBS containing 0.05% 
sodium azide using an IgG purification kit.
50
  
IgG molecules were bound to an affinity column in which protein G had been 
covalently immobilized to a polymeric support. The binding was facilitated by mixing the Ab 
with a buffer provided in the IgG purification kit. Molecules other than IgG were not bound to 
the column and were washed out. IgG was then eluted from the column using an elution buffer 
that dissociated the bound IgG.  
In the second step, IgG was transferred into PBS, with pH 7.4, by a “gel filtration” 
procedure using “D-Salt™ Excellulose™ Plastic Desalting Columns” provided in the IgG 
purification kit. During this procedure, molecules with molecular weights larger than 5000 Da 
which include IgG were eluted from the column faster, and were therefore separated from the 








2.3 Preparation of homogeneous IgG fractions 
As described earlier, polyclonal IgG consists of Abs with a wide range of specificities 
and affinities. In the course of the current work, polyclonal IgG was fractionated into 
homogenous populations using an immobilized-ligand affinity column. 
The column was made in-house according to the instructions provided by the 
manufacturer of the “PharmaLink™ Immobilization Kit”.
51
 Since oxazepam had been used as 
an Ag for preparation of anti-benzodiazepine Abs provided by most suppliers, oxazepam was 
coupled to the affinity column. The column consisted of diaminodipropyl amine (DADPA) 
that had been immobilized to 6% cross-linked agarose gel support. Oxazepam was covalently 
bound to the gel support by exploiting the “Mannich” reaction through condensation of 
oxazepam active hydrogen with formaldehyde and an amine.  
The oxazepam-affinity column was stored in PBS containing 0.05% sodium azide and 
was used within a year of preparation. The concentration of the protein eluted from the column 
with each eluent was monitored by measuring absorbance of the 0.5-mL collected fractions at 
280 nm, allowing baseline absorbance to be reached before applying the next eluting solution. 
In the first step, polyclonal IgG was loaded on the oxazepam affinity column in 
fractions of 1 mL volume or less. Due to the volume capacity of the column, there is a limit of 
1 mL sample application at a time, as indicated by the manufacturer.
51
 Each 1 mL fraction was 
incubated for one hour to allow oxazepam-specific IgG to bind to the column before eluting 
unbound IgGs with PBS. IgGs with no affinity for oxazepam were eluted from the column.  
After applying all of the polyclonal IgG to the column and removing unbound IgGs, the 
IgG molecules that were non-specifically bound to oxazepam were eluted from the column. 
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Elution of non-specific IgGs was performed using a series of solutions prepared in PBS 
(pH=7.4) in the following order: 0.1% Tween 20,
52
 10% ethylene glycol 
53 
and 0.3 M NaCl 
54
. 
Employing these solutions, hydrophobic and electrostatic interactions associated with non-
specific IgG were eliminated. 
Subsequently, oxazepam-specific IgG molecules were eluted from the column 
sequentially with 0.5 M NaCl / PBS followed by 1.0 M NaCl / PBS, acidic phosphate buffer 
(pH=2), 7M Urea (pH=8) and finally 6M Guanidine Hydrochloride (GnHCl) (pH=4).  
For over three decades, solutions with high salt concentrations along with acidic 
solutions have been used to recover specific Abs by disrupting the antibody-antigen affinity 
interactions.
54
 Nevertheless, low recoveries indicate that many Abs are still bound to the 
ligand. It has been suggested that the acidic buffer is not chaotropic enough to disrupt all Ab-
Ag interactions.
55 
Denaturing agents such as urea and GnHCl were employed to disrupt the 
interactions of the remaining bound Abs on the column. These compounds are known to 
disrupt intramolecular interactions essential for stabilization of folded protein structures.
56
 The 
tertiary structure of the Ab was unfolded by the urea solution, which resulted in partial 
denaturing of Ab.
56
 The extremely chaotropic solution of GnHCl completely denatured the 
protein by unfolding the secondary structure so that any IgG remaining on the affinity column 
after urea elution was eluted in this solvent.
55,  56
 
In the course of developing the method for preparation of specific IgG fractions from 
polyclonal IgG, one of the main challenges was refolding of the denatured Abs. Refolding was 
performed based on transferring the denatured fractions of Abs into PBS by ultrafiltration. 
GnHCl fractions were re-natured in two steps: first they were transferred into urea solution, 
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Imposing small changes to the procedure employed by H. Lord et al.
47, 48
, re-naturing 
specific IgG was improved. IgG fractions collected from acidic phosphate and urea eluents 
were diluted three times with PBS containing 0.05% sodium azide immediately after 
collection. GnHCl fractions were diluted with urea. All fractions were then kept at 4
o
C for 24 
hours after which they were completely transferred to the diluting solutions by centrifugation. 
GnHCl fractions went through the same cycle once more before being transferred to PBS 
buffer.  
The IgG fractions collected from various eluents were characterized in terms of 
specific binding, affinity and valence to evaluate the efficiency of various eluents in affinity 










2.4 Evaluation of antibody characteristics in solution 
Various fractions of Abs, including fractions collected from the oxazepam affinity 
column, generic IgG fractions, and polyclonal and monoclonal IgG fractions, which were 
raised against oxazepam, were evaluated in terms of their binding characteristics. The 
evaluations were performed by measuring the concentration of unbound oxazepam after 
incubation of a known amount of IgG with oxazepam standards at varying concentration. The 
drug concentration measurements were performed by an LC/MS/MS system. The results were 
used to select the IgG populations that were best suited for immobilization of glass rods.  
Abs were allowed to bind to oxazepam during a 90 minute incubation period. The drug 
that remained unbound in the samples (also termed “free drug” throughout this text) was 
separated from the drug bound to IgG by ultrafiltration. Membranes with molecular weight 
cut-offs of 30,000 Da, which is lower than the molecular weight of IgG (~150,000) and higher 
than that of the free drug (~ 300), were used for this purpose. The free drug concentration was 
measured using a LC/MS/MS system. Oxazepam concentrations were chosen in such a way as 
to be able to differentiate between initial and equilibrium concentrations of oxazepam in the 
upper range of concentrations and to have sufficient amounts of unbound drug for accurate 
analysis in the lower range of concentrations.  
The results of this test indicated the specific binding of each fraction of Ab to 
oxazepam at different Ab: drug molar ratios. The results were then employed to determine the 
affinity and valence of each fraction of Ab by Scatchard analysis. 
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2.5 Antibody immobilization 
Ab immobilization has been reported for enzyme-linked immunosorbent assays 
(ELISA), biosensors and immunoaffinity chromatography separations using different methods. 
Since Ab characteristics can be changed upon immobilization onto a surface, attempts have 
been made for developing methods that impose minimal change to Ab binding characteristics. 
Covalent immobilization of Abs has been performed using a linker compound such as 
glutaraldehyde (GA), while non-colvalent immobilization has commonly been performed by 
either adsorption to a surface or entrapment in a cross-linked matrix.
57, 58
 The main advantage 
of non-covalent immobilization is that these methods are more likely to retain the native 
composition of the Ab molecules. On the other hand, covalent immobilizations improve 
antibody binding capacity and stability by eliminating partial denaturation, leaching and 
displacement of the immobilized Abs which have been reported for non-covalent 
immobilization methods.
59, 60
 Covalent immobilization was therefore found to be more 
suitable for the purpose of this work.  The method was initially employed by H. Yuan et al.
61
 
for preparation of immunoaffinity SPME probes, but was modified by H. Lord et al.
47, 48
 and 
used for the current work. 
The immobilization method that was used in this work is based on covalent binding of 
Ab amino groups to activated silica surfaces of 4 mm diameter glass rods through GA (a 
cross-linking reagent). The silica surface was silanized with a fresh solution of APTES in 
ethanol. GA was then reacted with an activated-silica surface followed by exposing the GA-
activated surface to Ab solutions for Ab immobilization. Abs with high affinity and specificity 
were selected for the immobilization process based on the results of characteristic evaluation 
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experiments. SPME probes with generic IgG were also prepared for determination of non-
specific binding. Concentrations of 0.2 mg/mL or greater were used for Ab solutions. In the 
final step, a solution of ethanolamine was used to deactivate the remaining aldehyde groups on 
the probes surface. Readers are referred to publications of H. Lord et al.
47, 48
 for more details 


















2.6 Solid phase microextraction procedure 
In this section, the general procedure that was followed for microextraction of target 
drugs by immunoaffinity probes is described.  
The immunoaffinity probes, which were stored at 4
o
C in PBS containing 0.05% 
sodium azide, were allowed to equilibrate to room temperature before performing extraction. 
The extraction solutions were prepared on the day of the experiment by spiking appropriate 
amounts of drug standards into PBS or plasma. Probes were immersed in 20 mL disposable 
glass vials, each containing 15 mL of sample in the case of extraction from PBS. Extraction 
from plasma was performed in 96-well plates using 1.5 mL of sample in each well. Extraction 
was performed for 45 minutes during which the samples were agitated at 100 rpm on a 
Jeiotech shaker. The probes were then removed from the samples and rinsed thoroughly with 
nano-pure water to remove PBS salts or plasma proteins that might have stuck to the probes. 
The rinse also reduces carryover of non-extracted drugs to the desorption solution.  
Following the rinse, the probes were immersed in 500 µL of desorption solution which 
consisted of 75% methanol, 25% nano-pure water and 7.5 ng/mL internal standard 
(lorazepam). The composition of the desorption solution was reported to desorb >95% of 
extracted drugs while maintaining Abs affinity for the next experiments.
48
 A positive 
displacement repeater pipettor (Eppendorf  Repeater Plus) was used for reproducible and 
accurate dispensing of desorption solution. Desorption was also performed on the rotary 
shaker (100 rpm) for 15 minutes. Subsequently, the probes were rinsed briefly with water and 
stored in PBS containing 0.05% sodium azide at 4
o
C for at least 24 hours before the next 
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Desorption solution was then dried by flushing nitrogen through a 96-well plate dryer. 
The extracted drugs were reconstituted in smaller volumes of 75% methanol-25% water and 
injected to the LC/MS/MS system for separation and detection. The volume of reconstitution 
solution was dependant on the sensitivity required. A smaller volume (25 µL) was used when 
















2.7 Separation and detection of analytes 
Separation of analytes was performed using a Shimazu gradient LC system (model 
SLC 10 AVP) purchased from Mandel Scientific (Guelph, ON, Canada), an autosampler from 
CTC Analytics (model HTS PAL) purchased from Leap Scientific (Carrboro, NC, USA) with 
a 20 µL injection loop and a Symmetry Shield RP18 column (2.1 x 50 mm, 5 µm particle size) 
purchased from Waters Corporation (Milford, MA, USA). A gradient of two mobile phases (A 
containing 90% water, 10% acetonitrile and 0.1 % acetic acid and B containing 90% 
acetonitrile, 10% water and 0.1 % acetic acid) was used for separation of benzodiazepines. 
The run was started with 100% A which, after the first 30 seconds, was decreased to 10% A 
over 2 minutes. The mobile phase concentration was kept constant at 10% A for the next 1.5 
minutes, after which it was brought back to 100% A till the end of run. Total run time for each 
sample was 5.0 minutes and a flow rate of 0.5 mL/min was used throughout the run.  
Separated analytes were detected in a triple quadrupole tandem mass spectrometer 
(model API 3000) purchased from MDS Sciex (Concord, ON, Canada). Following 
electrospray ionization in positive ion mode, the analytes were analyzed with selected reaction 
monitoring. The transitions monitored for each target drug were as follows: 285.2/154.1 for 
diazepam, 271.1/140.0 for nordiazepam, 287.1/241.1 for oxazepam and 321.1/275.1 for 
lorazepam. The following conditions were used for MS: Nebulizer gas flow: 8 N2, nebulizer 
voltage: 4500 V, drying gas: 7 L/min N2, curtain gas: 12 N2, CAD gas: 12 Ar and ion source 
temperature: 250 
o
C. Figure 7 shows chromatograms of the target analytes. 
An electronic switching valve (model EV 750) and a six port valve (Rheodyne PEEK) 
from Waters (Milford, MA, USA) were employed to bypass the LC effluent for the first 
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minute of run time to the waste container. This procedure was performed for samples tested 
for IgG affinity in solution (contained 25% PBS) as well as samples from plasma extractions. 
In this way, the MS system was protected from salts or any other contaminants that could have 
been introduced to it from the samples.   
 
 
Figure 7: Sample chromatogram for diazepam (A), oxazepam (B), nordiazepam (C) 
and lorazepam (D).  
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Chapter 3 Results and Discussion 
Polyclonal and monoclonal Abs supplied by four different companies were evaluated 
for the percentage of specific IgG in polyclonal batches as well as binding characteristics in 
solution and were immobilized on glass rods. The immunoaffinity probes were also evaluated 



















3.1 Affinity purification of polyclonal IgG 
Purification of a fraction of polyclonal IgG with high affinity for benzodiazepines from 
the heterogeneous IgG pool was performed using an oxazepam-affinity column according to 
the process outlined in the Materials and Methods section. The result of a sample purification 
of Fitzgerald Polyclonal IgG is shown in Figure 8.  A similar trend was also observed after 










Figure 8: Sample of homogeneous IgG preparation from polyclonal IgG 
 
In Figure 8, the x-axis shows the number of fractions collected while the y-axis 
represents the amount of protein euted from the column. The y-axis values were determined 




 as the 
absorptivity coefficient of IgG as indicated in the literature. 
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As shown in Figure 8, acidic phosphate eluent has the highest yield of specific IgG. 
For this reason up to now, acidic phosphate had been the only eluent that provided enough 
active IgG for immobilization on glass rods.
 47, 48 
However, having improved the process of 
re-naturing Abs eluted by urea and GnHCl as described in section 2.3, I was able to collect 
relatively large amounts of active IgG from GnHCl elution as well. Thus, along with acidic 
phosphate IgG, specific IgG from GnHCl elution was utilized in this work for preparation of 
immunoaffinity probes. The results are shown in the next sections.
 
Also notable in Figure 8 is the high amount of protein eluted with PBS buffer (pH=7.4) 
after acidic phosphate elution. This step was performed to neutralize the affinity column in 
preparation for further elutions. Although no report of such behavior was found in the 
literature, the same trend was observed during affinity purification of polyclonal antibodies 
from all the suppliers used in this study.  Elution of IgG by PBS might be due to the charge 
induced on IgG molecules by acidic buffer. These charged molecules may be bound non-
specifically to the column and released following column neutralization by PBS.  
The results of affinity purification of PAb supplied from all four suppliers are 
compared in Table 1. The values are reported as the approximate percentage of total amount of 
PAb applied to the column.  As apparent from Table 1, PAb of different suppliers show 
analogous results with respect to affinity purification. The amounts of IgG recovered from 






Supplier Unbound IgG Non-specific IgG Acidic Phosphate Urea GnHCl 
Biotrend 76% 6% 9% 3% 6% 
Cortex 76% 7% 9% 3% 5% 
Fitzgerald 75% 7% 8% 4% 6% 
US Biological 74% 7% 9% 4% 6% 
 

















3.2 Affinity assessment of antibodies in solution 
The fractions collected from specific elutions during affinity purification of polyclonal 
Abs were characterized along with polyclonal and monoclonal Abs in terms of specific 
binding as mentioned previously in the text. A fraction of “unbound IgG” which was expected 
to have relatively small specific binding towards oxazepam, was also included in each test to 
assure the effectiveness of the affinity column. The specific binding data was used to 
determine the affinity and valance of the original and fractionated Abs by Scatchard analysis 
as explained in section 1.2.3. The Scatchard plot of US Biological Abs is shown in Figure 9. 
As shown in Figure 9, specific fractions of PAb show higher affinity towards 
oxazepam than the original PAb, confirming the effectiveness of the affinity purification 
method employed in the current research. 
Furthermore, Figure 9 demonstrates a higher degree of linearity for more homogeneous 
fractions of IgG. This is expected due to the fact that in a homogeneous population of Abs all 
molecules have identical affinities, and therefore produce a linear Scatchard plot while 
heterogeneous populations of Abs, that have a range of affinities, are expected to produce 
plots with curved shapes. Correlation coefficient (R
2
) values which indicate the degree of 
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 PAb Acidic phosphate Urea GnHCl MAb 
Correlation coefficient (R
2
) 0.734 0.844 0.936 0.974 0.998 
 
Table 2: Correlation coefficients associated with Scatchard plots of US Biological Abs 
demonstrated in Figure 9  
 
Table 2 clearly demonstrates improved linearity with increased homogeneity of affinity 
purified PAb fractions, which verifies that affinity purification of PAb has resulted in more 
homogeneous populations of Abs. Interestingly, the linearity of GnHCl fraction data is found 
to be relatively close to MAb’s which is expected to have a linear Scatchard plot (R
2 
= 1). 
Similarly, as indicated in Table 3, which provides affinity and valence values calculated from 
Scatchard analysis for all batches of Abs, linear regression analysis reveals comparable 
affinities for GnHCl and MAb fractions. The Ab valence, however, is found to be quite 
different for these two fractions. The “generic IgG” was also included in the test and was 
found to have an affinity of 6E06 (L/mol) and valence of 0.01 which are in line with affinity 















Urea GnHCl MAb  
K 8.29E07 8.01E06 9.17E07 1.28E08 3.31E08 3.59E08  
Biotrend n 0.122 0.024 0.421 0.453 0.593 1.35 
K 6.46E07 6.51E06 7.49E07 9.55E07 1.27E08 1.48E08  
Cortex n 0.152 0.051 0.290 0.383 0.425 1.49 
K 9.02E07 6.25E06 1.02E08 1.54E08 3.49E08 4.16E08  
Fitzgerald n 0.104 0.043 0.372 0.491 0.552 1.08 
K 7.20E07 5.58E06 8.65E07 8.69E07 1.17E08 1.43E08 US 
Biological 
n 0.117 0.014 0.472 0.614 0.805 1.68 
 
Table 3: Affinity, K (L/mol), and valance, n, of various IgG fractions in solution, calculated 
from Scatchard analysis data 
 
In comparing various Ab fractions provided by the same supplier, it is observed that 
the affinity and valence of Abs increase as homogeneity increases (Table 3). This trend, which 
demonstrates the efficiency of affinity purification of PAbs, is seen with Ab fractions from all 
four suppliers. The fraction of “unbound IgG” has the lowest affinity and valence compared to 
all other fractions of Ab from the same supplier, verifying that during the time that PAb was 
loaded on the oxazepam affinity column, no breakthrough of oxazepam-specific IgG was 
observed. The highest values for affinity and valance, on the other hand, are associated with 
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MAb fraction. It is also noted that GnHCl fraction, has similar affinity towards oxazepam 
compared to MAb. However, it has smaller valance than MAb fraction.  
Although the same trend is observed for various fractions of the Abs from the same 
supplier in terms of affinity and valance values, different values are estimated for Abs of the 
same type obtained from various companies. This is expected as Abs from different suppliers 
had been produced in different conditions. Abs provided from a single company could also 
have different binding properties even if the same animal and the same conditions are used for 
immunization. This is due to the fact that the response of a living species to a foreign agent is 
different at different times. Therefore, unless Abs produced during one immunization 
procedure, holding the same lot number, are obtained from a company, the binding 
characteristics are expected to be different. 
From Table 3, it is also noted that the valence values estimated for the Abs are 
comparable for Abs of the same type obtained from various suppliers. As stated previously, 
the valence of a homogeneous population of IgG is ideally equal to 2, since an IgG molecule 
has two equal binding sites. The valence values for MAb fractions obtained from all four 
suppliers were greater than 1.00 while PAb valance values were smaller than 0.200. 
 The affinity assessment of the Abs was initially used for evaluation of the affinity 
purification method and for comparing Abs supplied from various companies in terms of their 
binding properties. However, the results were also used for selecting appropriate fractions of 
Abs for immobilization onto the glass rods. Since the immobilization process took a minimum 
of one week per batch of Ab, the batches with low affinities (in the range of E06) were 
excluded from the immobilization process. Finally, the affinity values calculated from 
Scatchard data were used in the current work to determine the concentration of free oxazepam 
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that would saturate 50% of Abs’ binding sites as described in section 1.2.3. Calculating these 
values (Table 4) allowed for estimation of the range of sample concentrations for which the 
Abs can be used to extract free oxazepam. Based on the values reported in Table 4, the Abs 
were expected to be appropriate for quantification of benzodiazepines in the range of low to 
sub ng/mL concentrations.   
 
Oxazepam concentration (ng/mL) at 
50% saturation 
PAb  Acidic Phosphate Urea GnHCl MAb  
Biotrend 3.59 3.19 2.87 0.96 0.96 
Cortex 4.78 4.10 3.19 2.87 2.87 
Fitzgerald 3.19 2.87 2.87 0.96 0.72 
US Biological 4.10 3.59 3.19 2.87 2.87 
 
Table 4: Estimates of oxazepam concentrations that saturate 50% of Abs’ binding sites for 








3.3 Evaluation of immobilized antibodies  
 The binding characteristics of Abs employed in preparation of immunoaffinity SPME 
probes had been previously evaluated in terms of affinity and probe capacity using two 
different methods of regression.
47
 Since non-linear regression to Sips equation is the best 
known method to date for describing the binding characteristics of Abs, it was used for these 
evaluations. Cross-reactivity of the immunoaffinity probes was also evaluated for different 
combinations of two of the three drugs at a time.  
3.3.1 Calibration of immunoaffinity probes in buffer 
Immunoaffinity SPME probes were calibrated for oxazepam, diazepam and 
nordiazepam in PBS buffer individually. For each test, five different concentrations of each 
drug were prepared in the range of 0.01 – 2 ng/mL. Three probes from each type of Ab were 
used for extraction from each concentration. Calibration profiles of Fitzgerald Ab probes for 
each drug are demonstrated in Figure 10. Probes prepared with generic IgG, which has no 
specific affinity for benzodiazepines, were used in calibration tests to determine the amount of 
non-specific binding. As can been seen from the graphs in Figure 10, the amount of drug 
extracted by generic IgG probes were found to be insignificant in the range of concentrations 
used for calibration of probes. Thus, elimination of drugs that were non-specifically bound to 


























Figure 10: Calibration profiles of Fitzgerald and generic IgG probes for drugs of interest 
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The calibration data were fitted to the Sips equation as discussed in section 2.1 and the 
values of K  (probe affinity), b  (probe capacity) and a  (heterogeneity index) were calculated. 
Linear regression analysis of immunoaffinity probe calibration can be performed based on the 
reciprocal of the Langmuir equation. However, as mentioned previously, the Langmuir 
equation does not consider Ab heterogeneity and therefore, in this work, non-linear regression 
to the Sips equation was chosen. It should be noted that based on previous research performed 
on Cortex Abs, for Abs with 78.0≥a , affinity and capacity values estimated by either of the 
equations are expected to be similar.
46
 
Table 5 summarizes the values calculated from regression to the Sips equation for 
Fitzgerald immunoaffinity probes. From the values reported in Table 5, it is apparent that the 
homogeneity, capacity and affinity values of Fitzgerald immunoaffinity probes (represented 
bya ,b andK  respectively) are increased for fractions purified from PAb, as more oxazepam-
specific fractions of Abs are exploited for extraction of each drug (Table 5). The trend 
observed for these values confirms the success of the affinity purification procedure for 
preparation of more homogeneous fractions of Abs with higher affinities towards 
benzodiazepines. Comparing the binding values of each probe type for the three different 
target drugs in Table 5, equal performance is observed for diazepam and nordiazepam. In the 
case of oxazepam extraction, lower affinities and larger capacities are calculated with respect 
to the other two drugs. The heterogeneity indices are slightly higher for diazepam and 
nordiazepam although the range is comparable for all three drugs.      
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Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.586 0.611 0.590 
b  (pg) 156 54.4 33.8 




K  (L/mol) 1.02E09 8.53E09 7.96E09 
a  0.702 0.852 0.836 
b  (pg) 261 83.4 75.9 




K  (L/mol) 2.15E09 8.69E09 1.21E10 
a  0.793 0.907 0.902 
b  (pg) 283 93.0 85.0 




K  (L/mol) 2.83E09 1.18E10 1.21E10 
a  0.922 0.956 0.956 
b  (pg) 317 115 93.9 




K  (L/mol) 4.85E09 1.30E10 1.39E10 
a  0.971 0.994 0.989 
b  (pg) 593 213 204 




K  (L/mol) 5.51E09 6.47E09 7.34E09 
a  0.199 0.200 0.193 
b  (pg) 18.5 20.1 18.0 




K  (L/mol) 2.87E06 2.79E06 3.03E06 




MAb probes exhibit lower affinities for diazepam and nordiazepam than PAb and 
affinity purified PAb probes, which is not unusual.
25
 The affinity values of MAb for 
oxazepam are comparable to affinity values of GnHCl probes and are in line with the values 
calculated from Scatchard analysis of Abs prior to immobilization (Table 3). As expected, 
MAb probes are the most homogeneous and have the largest capacities (Table 5). 
Generic IgG probes show incredibly low homogeneity for drugs of interest which is 
expected since generic IgG is a mixture of IgG molecules that exist in the serum of non-
immunized animal and therefore, have been produced against a wide variety of compounds. 
For the same reason, the capacity and affinity values of these probes are also found to be low. 
The affinity value of immobilized generic IgG probes are in line with the values obtained from 
Scatchard analysis for free Ab. 
From a more general point of view, the data in Table 5 demonstrate that the biospecific 
activity of Abs toward oxazepam has been retained during immobilization, confirming the 
suitability of the immobilization procedure for this work. Comparing affinity values for 
Fitzgerald Abs in Tables 3 and 5, similar trends are observed for both immobilized and free 
Abs. The absolute values of affinity, on the other, have increased after immobilization (Table 
5). The difference in affinity values of the same fractions of Abs before and after 
immobilization could be due to the orientation of immobilized Abs on a solid support, which 
increases the number of sterically available antigenic sites of Abs, as opposed to random 
distribution of free Abs in solution, which can cause more steric hindrance for Ags to bind to 
Abs. Another reason for this discrepancy could be the difference in the accuracies of methods 
used for regression analysis. As mentioned previously in the text, all Abs, including MAbs, 
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exhibit a range of affinities. This range, which is larger for more heterogeneous fractions of 
Abs, is not taken into account in Scatchard analysis. In the Sips equation, on the other hand, 
distribution of affinities is considered and thus, more accurate estimates can be calculated 
from regression analysis of the Sips equation. 
Table 5 also demonstrates the difference between capacity and affinity of 
immunoaffinity probes. These two terms, which are often confused, are not directly dependent 
on each other. As shown in Table 5, the capacity values of MAb probes are higher than all 
other types of probes for all three benzodiazepines, while their affinities for diazepam and 
nordiazepam are significantly lower than other Fitzgerald Ab probes. The capacity of an 
immunosorbent is defined as the number of specific immobilized Abs that Ag molecules can 
access.
62
 It is different from the total number of immobilized Abs, termed “bonding density”, 
because random orientation and steric hindrance prevent Ag molecules from accessing all Ab 
molecules immobilized on the sorbent.
62
 Based on the definition, the capacity of 
immunoaffinity probes depend on the concentration of specific Abs in the fraction of Abs used 
for preparation of the probes. Therefore, MAbs are expected to have higher capacities than 
PAbs, even for drugs to which they bind with lower affinities.  
The values of heterogeneity index, affinity and capacity calculated from the Sips 
equation for Abs obtained from other suppliers are reported in Tables 6 to 8.Although the 
estimated values are different for each type of probe, the trends observed for Fitzgerald 
immunoaffinity probes, as explained in this section, are also noted for Biotrend and US 
Biological Ab probes. Cortex probes also follow the trends observed for other immunoaffinity 
probes except for diazepam extraction. As Table 7 shows, Cortex probes extract higher 
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amounts of diazepam than the other two drugs. In case of all other probes, oxazepam is 
extracted more than diazepam and nordiazepam. 
Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.548 0.694 0.679 
b  (pg) 159 80.1 54.0 




K  (L/mol) 9.52E08 8.07E09 8.41E09 
a  0.699 0.881 0.859 
b  (pg) 258 122 107 




K  (L/mol) 1.77E09 9.70E09 1.06E10 
a  0.786 0.922 0.907 
b  (pg) 273 189 162 




K  (L/mol) 2.81E09 1.25E10 1.20E10 
a  0.943 0.970 0.965 
b  (pg) 349 247 191 




K  (L/mol) 4.03E09 1.37E10 1.28E10 
a  0.985 0.996 0.994 
b  (pg) 921 433 409 




K  (L/mol) 5.15E09 5.30E09 5.07E09 
 





Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.509 0.667 0.609 
b  (pg) 150 125 90.5 




K  (L/mol) 6.55E08 5.86E09 5.69E09 
a  0.612 0.875 0.805 
b  (pg) 189 191 129 




K  (L/mol) 8.62E08 6.22E09 6.19E09 
a  0.753 0.938 0.892 
b  (pg) 229 271 134 




K  (L/mol) 1.22E09 6.74E09 6.51E09 
a  0.896 0.977 0.951 
b  (pg) 255 338 172 




K  (L/mol) 2.09E09 7.11E10 7.10E09 
a  0.972 0.999 0.987 
b  (pg) 980 426 311 




K  (L/mol) 2.53E09 4.68E09 4.46E09 
 






Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.527 0.620 0.568 
b  (pg) 144 54.8 40.0 




K  (L/mol) 8.21E08 3.42E09 3.98E09 
a  0.724 0.862 0.798 
b  (pg) 440 150 65.8 




K  (L/mol) 9.01E08 3.76E09 5.02E09 
a  0.891 0.968 0.927 
b  (pg) 451 171 97.6 




K  (L/mol) 1.11E09 4.22E09 5.26E09 
a  0.920 0.971 0.959 
b  (pg) 486 180 125 




K  (L/mol) 1.46E09 4.59E09 5.42E09 
a  0.972 0.989 0.978 
b  (pg) 1265 320 296 




K  (L/mol) 1.62E09 9.42E08 2.41E09 
 





3.3.2 Cross-reactivity assessment 
In clinical samples, drugs other than the analyte of interest are commonly present. 
With respect to the chemical structure, these drugs can be similar, such as analyte metabolites, 
or totally different. Thus, it is of importance to examine performance of the probes while more 
than one analyte is present in the sample.  
A series of experiments were performed to compare cross-reactivity of immunoaffinity 
probes. All Abs were indicated by the suppliers to be 100% cross-reactive for 
benzodiazepines. In addition to the probes described previously in the text, a new batch was 
included in the cross-reactivity experiments. This batch was prepared with “acidic phosphate” 
fraction of oxazepam-specific PAb obtained from Cortex. The Ab was indicated by the 
supplier to be specific for oxazepam with low cross-reactivity for other benzodiazepines, 
including diazepam and nordiazepam. Thus, its performance was of interest in terms of cross-
reactivity compared to other Abs that were recognized as cross-reactive for all 
benzodiazepines. In this text, the latter Abs are termed “highly cross-reactive” while 
“oxazepam-specific” refers to probes prepared with less cross-reactive Abs. 
The performance of immunoaffinity probes in the presence of diazepam and its two 
major metabolites, oxazepam and nordiazepam, has been evaluated in earlier studies.
47
 In the 
current work, cross-reactivity of probes for each one of the target analytes was evaluated in the 
presence of another benzodiazepine. In each experiment, the probes were exposed to 15mL 
samples containing the target drug at a constant concentration of 0.2 ng/mL and the cross-
reactant at 7 different concentrations ranging from 0 to 10 ng/mL. Cross-reactivity was 
measured as the concentration of the cross-reactant that inhibits extraction of the analyte by 
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50%. Since all probes, except for “oxazepam-specific” ones were prepared with highly cross 
reactive Abs, the cross-reactivity of probes with the same type of Ab obtained from various 
suppliers were expected to be in the same range. The results are summarized in Table 9. 
Consistent results were obtained from highly cross-reactive Abs from various companies. 
Hence, the average cross-reactivity values are reported for various types of Abs obtained from 
all four suppliers (Table 9). 
 
Cross-reactivity (ng/mL) 












Urea GnHCl MAb 
Dz 1 < 0.2 < 0.2  0.2 < 1 < 1 Ox 
Nd < 1 < 0.2 < 0.2 < 0.2 < 0.2 0.2 
Ox < 0.2 0.2 0.2 < 0.2 < 0.2 < 1 Dz 
Nd < 1 0.2 <0.2 <0.2 < 0.2 < 0.2 
Ox < 0.2 0.2 0.2 < 0.2 < 0.2 < 7.5 Nd. 
Dz 0.2 < 0.2 < 0.2 < 0.2 < 0.2 < 0.2 
 
Table 9: Results of cross-reactivity experiments for immunoaffinity probes of different types. 
(Ox: oxazepam, Dz: diazepam, Nd: nordiazepam) 
 
To better demonstrate the displacement of an analyte by a cross-reactant, graphical 
results of two types of Cortex probes for oxazepam extraction in the presence of diazepam at 


















































































As the results clearly demonstrate, for oxazepam-specific probes, the 50% 
displacement of oxazepam by either of the other drugs occurred at much higher concentrations 
(nearly five times higher) than for the highly cross-reactive probes. Furthermore, 50% 
displacement of diazepam and nordiazepam was observed at oxazepam concentrations as low 
as 0.2 ng/mL. This suggests that the “oxazepam-specific” Ab, as described by the supplier, is 
in fact oxazepam-specific. When diazepam and nordiazepam were competing for Ab sites, 
oxazepam-specific probes were found to be more cross-reactive for nordiazepam rather than 
diazepam, while highly cross-reactive probes treated both analytes equally (Table 9). This 
result is in line with cross-reactivity values reported in Ab specification sheets provided by 
their suppliers. 
As for highly cross-reactive probes, the PAb and affinity purified PAb probes were 
found to be equally cross-reactive for diazepam and nordiazepam. For oxazepam, on the other 
hand, the affinity-purified probes (acidic phosphate, urea and GnHCl) were found to be more 
cross-reactive towards oxazepam than the other two analytes. Once again, the results confirm 
that Abs purified on the oxazepam affinity column contained larger fractions of oxazepam-
specific Ab than PAb fractions. Cross-reactivity of PAb probes was found to be comparable 
for all three drugs.   
Similar to PAbs, MAbs were specified by the suppliers to be cross-reactive for all 
benzodiazepines. However, the cross-reactivity values of MAbs were not indicated in the Ab 
specification sheets. Based on the results of the cross-reactivity experiments (Table 9), MAbs 
have similar cross-reactivity for diazepam and nordiazepam. MAb probes were found to 
interact equally with diazepam and oxazepam when these two drugs were present in the same 
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samples. Nevertheless, it was observed that for MAb probes, nordiazepam was displaced by 
oxazepam at high concentrations (approximately 7.5 ng/mL) while oxazepam displacement 
(50%) by nordiazepam occurred at 0.2 ng/mL. 
Apart from calculations for cross-reactivity, it was noted that oxazepam-specific 
probes extracted more than twice the amount of oxazepam as was extracted by highly cross-
reactive probes in the absence of the competing drug (diazepam or nordiazepam). Thus, it is 
concluded that oxazepam-specific probes are more suitable for oxazepam extraction when 
diazepam and nordiazepam are at lower concentrations. It should be noted that even at the 
highest concentration used for this experiment (10 ng/mL), neither diazepam nor nordiazepam 










3.4 Evaluation of extraction and desorption conditions 
3.4.1 Evaluation of extraction conditions  
As described in Chapter 2, the probes were used for extraction from 15 mL spiked PBS 
buffer samples. Based on sample concentrations, this volume had been chosen in previous 
studies of immunoaffinity probes because depletion of analytes was found to be negligible.
47
 
In order to have negligible depletion of analytes from extraction samples, the amount of drugs 
extracted by SPME probes should be comparable to the experimental error.
63
 Such conditions 
are desired to generate consistent calibration profiles that are independent of sample volume. 
Since the conditions that allow negligible depletion have been studied for immunoaffinity 
probes in an earlier study, they will not be discussed further.
47
  
Extraction from plasma samples, on the other hand, was performed from 1.5 mL 
samples mainly due to the limited volume of plasma that was available. The conditions for 
negligible depletion of analytes from plasma samples were carefully investigated. Assuming 
95% protein-binding for the drugs in plasma, the amount of free drugs extracted by the probes 
were less than the experimental error which was calculated to be below 10% (see section 3.6). 
The amount of time required for the probes to reach equilibrium during the extraction 
process was determined for various probes. Extraction was performed from 15 mL sample of 
0.1 ng/mL oxazepam on a shaker with 100 rpm. Vigorous agitation is expected to speed up the 
equilibration by facilitating mass transport conditions. However, previous studies on 
immunoaffinity probes have shown no improvement in extraction rates beyond 100 rpm. Thus, 
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 Extraction time profile: Biotrend probes





























































it can be concluded that the rate of extraction for agitated samples is controlled by the kinetics 
of antigen-antibody reaction rather than mass transport.  
The extraction time was varied from 1 minute to 45 minutes at six time points. The 
equilibrium time profile of Biotrend probes is shown in Figure 12 as an example. Eliminating 
MAb probes results, the y-axis is extended on Figure 12-B to better show the equilibration 
time profiles of other probe types. 
The equilibrium times for 
different types of probes were 
estimated based on the times that a 
plateau was reached. Based on 
Figure 12, the equilibration times 
are as follows: 10 minutes (PAb), 
20 minutes (Acidic phosphate and 
Urea), 30 minutes (GnHCl) and 45 
minutes or longer (MAb). As 
expected, probes with higher 
capacities are associated with 
longer equilibrium times. The 
equilibration time profiles for Abs 
obtained from different suppliers 
were comparable.   





Comparing the amounts extracted by the probes at the plateaus with the maximum 
capacity of the probes for oxazepam (Table 6), it is confirmed that the plateaus were not 
caused by probe saturation. It has been known for over three decades that the rate of 
dissociation of Ab-Ag complex determines the Ab affinity towards a hapten. The association 
rate, on the other hand, is fairly constant for Abs with different affinities.
64
 Thus, different 
equilibrium times observed for Abs with different affinities are mainly due to different 
capacities of the probes. Shorter equilibrium times are also expected for extraction of 
diazepam and nordiazepam due to their smaller probe capacities (Table 6). 
Based on the results, extraction time of 45 minutes was used in this study to allow 
equilibrium extraction for all probes including MAb. The extraction time can be shortened to 
30 minutes when MAb probes are not employed in an experiment. 
3.4.2 Evaluation of desorption conditions  
Extracted analytes were desorbed in 500 µL of 75% methanol containing internal 
standard (lorazepam). The volume and composition of the desorption solution were 
determined in earlier studies as a good compromise allowing 95% of extracted drugs to be 
desorbed.
47
 The desorption time profiles for the immunoaffinity probes were evaluated at six 
time points ranging from 1 minute to 45 minutes at 100 rpm. Prior to desorption, all probes 
were immersed in 15 mL samples of 0.1 ng/mL oxazepam for 45 minutes on a shaker at 100 
rpm. The desorption profiles of Biotrend probes are shown in Figure 13. As shown in this 
figure, the time required for desorption of extracted drugs increases as probe affinity increases: 
15 minutes (MAb probes), between 10 to 15 minutes (GnHCl probes), 10 minutes (Acidic 
phosphate and Urea probes) and 5 minutes (PAb probes).  
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As mentioned earlier, Ab affinity, which is inversely proportional to the dissociation 
rate constant, is mainly dependent on the rate of dissociation of the Ab-Ag complex. 
Therefore, Abs with higher affinities are expected to have slower dissociations which is in line 
with the results shown in Figure 13. The probes from other suppliers performed similarly. The 
longest desorption time observed for the probes was 15 minutes and was used throughout this 







































































3.5 Evaluation of probe stability  
Abs are fairly expensive and preparation of immunoaffinity probes is laborious and 
time consuming. Therefore, it was of importance to evaluate probe stability upon storage and 
reusability following a number of extractions. The extraction efficiency of probes was studied 
in earlier works for up to three months storage time.
47
 In the current study, this experiment 
was extended for up to six months from the day of preparation of the first set of rods. Each 
month, a set of the so called “fresh” probes were prepared from Cortex PAb which was stored 
in PBS buffer and 0.05% sodium azide at 4
o
C. Their performance on extraction of oxazepam 
was compared to the so called “old” probes that had been prepared at the beginning of the six-
month period. The latter probes were prepared from the same batch of Abs and were stored in 
PBS buffer containing 0.05% sodium azide at 4
 o
C. The experiment was performed once every 
month employing a set of four “old” probes that had never been employed for extraction 
before and a set of four “fresh” rods. The results obtained over a six month period are shown 
in Figure 14.  
Figure 14: Evaluation of probe stability in six months 
 
 72 
No significant decrease in extraction efficiencies was observed for old probes over the 
first three months (Figure 14). However, the extraction efficiency was considerably lowered 
after the third month. By the end of the six-month period, the extraction efficiency of “old” 
probes was reduced to 75% of the first month’s extraction efficiency. It can be concluded that 
the probes can be used for extraction within three months of their preparation without a major 
decrease in extraction efficiency.  
A gradual decrease in extraction efficiency is observed for “fresh” probes after the first 
month (Figure 14). The results demonstrate that during the three-month storage, immobilized 
Abs retain extraction efficiency while free Abs, stored in the same conditions, gradually lose 
their extraction efficiency by 30%. After the three-month period, the free and immobilized 
Abs’ performance is comparable.  
The reusability of immunoaffinity SPME probes for multiple extractions has been 
evaluated in previous studies in which the probes were found to have lost 30% of their 










3.6 Method validation 
The method developed for extraction and quantification of benzodiazepines in this 
research was validated by estimating the precision, limit of detection and dynamic range of the 
method. Precision of the method using various types of Abs was estimated at 12 % based on 
relative standard deviation (RSD). 
The limit of detection (LOD) was estimated at approximately 0.01ng/mL as determined 
by the sensitivity of the tandem mass spectrometry system. LOD was calculated based on 
three times the standard deviation of samples containing 0.01 ng/mL of each drug individually 
in PBS buffer.  
Fitting the calibration data to the non-linear Sips equation allowed for larger dynamic 
range. Thus, the dynamic range of the method was extended to concentrations that result in 
80-90% saturation of the probes. The upper limit of quantification (ULOQ) of the probes is 
summarized in Table 10 along with the method’s precision and LOD. The values reported for 













Antibody type Validation parameters  Oxazepam Diazepam Nordiazepam 
% RSD 8% 9% 7% 
LOD (ng/mL) 0.001 0.001 0.007 
 
PAb 
ULOQ (ng/mL) 0.5 0.2 0.2 
% RSD 8% 6% 7% 




ULOQ (ng/mL) 0.5 0.2 0.1 
% RSD 5% 7% 5% 
LOD (ng/mL) 0.002 0.005 0.002 
 
Urea 
ULOQ (ng/mL) 0.5 0.2 0.1 
% RSD 5% 5% 8% 
LOD (ng/mL) 0.001 0.007 0.006 
 
GnHCl 
ULOQ (ng/mL) 0.5 0.2 0.1 
% RSD 12% 10% 10% 
LOD (ng/mL) 0.004 0.006 0.003 
 
MAb 
ULOQ (ng/mL) 0.5 0.2 0.2 
 
Table 10: Summary of validation data for immunoaffinity probes employed in this research 
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3.7 Application of immunoaffinity probes for drug analysis in 
plasma 
Following the evaluation of immunoaffinity probes in buffer, the probes’ applicability 
for drug analysis in biological fluids was examined by direct extraction of benzodiazepines 
from plasma. Therapeutic and toxic effects of drugs are usually found to have a good 
correlation with the drug concentrations in plasma. As a result, plasma is the most commonly 
sampled body fluid in drug analysis and was therefore chosen for this research. Plasma 
consists of large amounts of proteins to which the drugs can bind to various degrees. In the 
SPME technique, a small portion of the free drug is extracted. This is advantageous in drug 
analysis since pharmacological effects of drugs in plasma are exhibited by the unbound 
fraction of the drugs.  
Immunoaffinity probes were used for extraction from 1.5 mL plasma samples which 
had been spiked with one of the target benzodiazepines. Three probes of each probe type were 
used for extraction from plasma samples with seven concentrations ranging from 0.01 ng/mL 
to 5.0 ng/mL. The concentration range of extraction solutions was extended to 5.0 ng/mL as it 
was observed that, unlike the calibration experiment in buffer, the saturation plateau was not 
reached at 2.0 ng/mL. Calibration profiles of Fitzgerald probes for each of the target drugs are 
shown in Figure 15. The data are fitted to the Sips equation as was done for the calibration 
experiment in buffer. The concentrations of free Ag (in the x-axis) were calculated assuming 


























Figure 15: Calibration profiles of Fitzgerald probes for benzodiazepines in plasma  
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In spite of the high homogeneity and large capacity values of MAb probes for 
benzodiazepines in PBS buffer (Table 5), MAb probes were found to be inappropriate for 
extraction of benzodiazepines from plasma and were therefore excluded from the calibration 
curves represented in Figure 15. The same situation was observed when MAb immunoaffinity 
probes prepared with US Biological MAbs were employed for extraction from urine.
48
  
Following the calibration experiment in plasma, the performance of MAb 
immunoaffinity probes were examined for extraction from buffer. The results were similar to 
the extraction from plasma samples which indicates that the plasma matrix has imposed an 
irreversible impact on the MAb probes. The cause of such behavior is unknown, however, it is 
suspected that one or a group of compounds present in plasma and urine interfere with the 
binding of drugs to antigenic sites of MAbs.
48
 PAbs and their purified fractions suffer from 
such interference as well. However, due to their higher heterogeneity, they may exhibit 
alternative binding sites for which the matrix constituents do not compete with the analyte.   
Comparing the results of calibration of Fitzgerald immunoaffinity probes in plasma 
(Figure 15) with the results in buffer (Figure 10), it is apparent that the amounts of drugs 
extracted from plasma samples are significantly lower than the amounts extracted from buffer 
using the same probes. This is due to high plasma protein binding of benzodiazepines which is 
in the range of 95-99%.
65,66
 Thus, the amounts of drugs extracted from plasma samples are 
expected to be 95-99% less than the amounts extracted from PBS buffer with equal 
concentration of drugs.  
As reported in section 3.3.1, amounts of oxazepam extracted by the different types of 
immunoaffinity probes are higher than diazepam and nordiazepam. The same trend would 
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have been expected for extraction from plasma if all three drugs were bound to plasma 
proteins to the same extent. As Figure 15 demonstrates, the amounts of diazepam extracted by 
Fitzgerald probes are nearly twice the amount of extracted oxazepam and three times the 
amount of extracted nordiazepam. Biotrend, Cortex and US Biological immunoaffinity probes 
have shown the same trend as well. Based on these results, it can be concluded that diazepam 
protein binding was less than the other two drugs.  
Comparing Figure 10 and Figure 15 for each drug, it is also evident that the shapes of 
the antibody-antigen binding curves are different. For most types of immunoaffinity probes, 
saturation was reached at 0.5 ng/mL in buffer. In the case of extraction from plasma, on the 
other hand, the probes were saturated at 2.0 ng/mL or higher concentrations, generating 
smoother binding curves. Based on the shape of the calibration curves presented in Figure 15, 
lower values are expected for affinity of Fitzgerald probes in plasma. The affinity values along 
with capacities and heterogeneity indices of the immunoaffinity probes are estimated for 
extraction from plasma samples by non-linear regression of calibration data to the Sips 
equation and are presented in Tables 11 to 14. 
The affinity values of various types of probes for benzodiazepines are found to be less 
in plasma than in buffer (Tables 5 to 8 and 9 to 12). Competition of plasma constituents for 
some antigenic sites of the Abs was suggested as a reason for failure of the MAb probes to 
perform adequately in plasma. Lower affinity values of other probes in plasma can also be 








Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.572 0.617 0.601 
b  (pg) 1.51 3.21 0.805 




K  (L/mol) 5.41E08 6.49E08 4.98E08 
a  0.705 0.849 0.812 
b  (pg) 2.50 5.46 2.13 




K  (L/mol) 7.22E08 1.53E09 1.43E09 
a  0.766 0.911 0.899 
b  (pg) 2.97 6.54 2.51 




K  (L/mol) 7.42E08 1.58E09 2.00E09 
a  0.919 0.958 0.950 
b  (pg) 3.55 7.81 2.73 




K  (L/mol) 1.15E09 1.99E09 2.75E09 
 
Table 11: Heterogeneity index ( a ), capacity (b ) and affinity (K) values of Fitzgerald 








Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.512 0.688 0.682 
b  (pg) 1.44 3.92 1.08 




K  (L/mol) 5.14E08 6.60E08 5.60E08 
a  0.709 0.885 0.860 
b  (pg) 2.97 6.13 1.63 




K  (L/mol) 5.97E08 1.72E09 1.18E09 
a  0.763 0.902 0.898 
b  (pg) 2.59 9.05 3.55 




K  (L/mol) 6.92E08 2.04E09 1.56E09 
a  0.929 0.968 0.959 
b  (pg) 3.16 11.72 3.78 




K  (L/mol) 1.03E09 2.55E09 2.31E09 
 
Table 12: Heterogeneity index ( a ), capacity (b ) and affinity (K) values of Biotrend 








Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.516 0.674 0.599 
b  (pg) 1.43 5.87 1.59 




K  (L/mol) 2.78E08 5.47E08 6.94E08 
a  0.609 0.890 0.824 
b  1.90 9.41 1.89 




K  (L/mol) 4.22E08 7.60E08 8.10E08 
a  0.745 0.933 0.897 
b  (pg) 2.16 12.9 2.57 




K  (L/mol) 7.21E08 9.62E08 1.13E09 
a  0.902 0.980 0.964 
b  (pg) 2.38 18.8 3.12 




K  (L/mol) 8.84E08 1.41E09 1.52E09 
 
Table 13: Heterogeneity index ( a ), capacity (b ) and affinity (K) values of Cortex 








Antibody type Sips equation values  Oxazepam Diazepam Nordiazepam 
a  0.510 0.628 0.573 
b  (pg) 1.39 2.36 0.640 




K  (L/mol) 4.22E08 1.03E09 1.58E09 
a  0.716 0.867 0.800 
b  (pg) 4.12 6.96 0.924 




K  (L/mol) 5.22E08 1.10E09 1.92E09 
a  0.886 0.974 0.922 
b  (pg) 4.47 8.05 1.38 




K  (L/mol) 5.80E08 1.28E09 2.42E09 
a  0.924 0.980 0.962 
b  (pg) 4.60 8.97 2.06 




K  (L/mol) 9.41E08 1.47E09 2.67E09 
 
Table 14: Heterogeneity index (a ), capacity (b ) and affinity (K) values of US Biological 






While the decrease in probe affinities in plasma were found to be as large as an order 
of magnitude, relative to the values in buffer, the amounts of extracted drugs were reduced to 
below 1% for oxazepam, 5-7% for diazepam and 1-2% for nordiazepam (Tables 9-12). The 
low amounts extracted from plasma are expected to be based on the high plasma protein 
binding of benzodiazepines as stated earlier in the text. The heterogeneity indices are in the 
same range for plasma and buffer samples and are increased for probes with the purity of Abs 
used for preparation of the probes. Despite the differences in the values calculated from the 
Sips equation for buffer and plasma, the patterns are analogous in terms of changes in affinity 
and capacity values for different types of probes and different drugs.  
The sensitivity of the detector used for the analysis of extracted drugs determined the 
LOD which was calculated based on 3 times the standard deviation for extractions from 0.01 
ng/mL samples. The LOD for extraction from plasma samples ranged from 0.001 ng/mL to 
0.008 ng/mL. Since calibration data are fitted to a non-linear equation, the dynamic range was 
extended to 2 ng/mL at which 80-90% of antigenic sites of Abs were bound to drugs (80-90% 
saturation). It should be noted that this upper limit of quantification (ULOQ) depends on the 
affinity of the Abs. Lower affinity values (as observed for plasma samples) result in saturation 
at higher concentrations which subsequently result in higher limits of quantification. The 
precision of probes in plasma (estimated by measuring %RSD) was calculated to be less than 
10% for all three drugs.  
The results demonstrate that the immunoaffinity probes prepared with PAb and 
affinity-purified fractions of PAb can be successfully employed for measuring 




Chapter 4 Conclusions 
Development of a SPME device that would allow for direct extraction of trace levels of 
pharmaceuticals from biological matrices is an important step towards improvement of sample 
preparation in drug analysis. Immunoaffinity SPME probes were evaluated for such analyses 
in this study.  
A purification method had been developed based on affinity chromatography for 
fractionation of polyclonal antibodies into more homogeneous fractions.
47
 During the course 
of this work, this method was improved and resulted in production of three more 
homogeneous fractions of antibodies with higher affinities and capacities towards 
benzodiazepines.    
As antibodies serve as the extraction phase, evaluation of their binding characteristics was 
important for the purpose of this research. It was also of great interest to evaluate MAbs along 
with PAbs from different suppliers for binding characteristics and performance upon 
immobilization on silica probes. Five different types of immunoaffinity probes were prepared 
with Abs provided by each supplier. The probe types were as follows: PAb, MAb and three 
affinity purified fractions of PAb referred to as acidic phosphate, urea and GnHCl. The values 
estimated for valance and affinity of the Abs towards oxazepam prior to immobilization were 
found to be comparable for Abs of the same type obtained from different suppliers. The 
affinity and valance values increased in the following order: PAb < acidic phosphate < urea < 
GnHCl < MAb.   
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The binding characteristics of Abs were evaluated following immobilization to glass 
rods. For each batch of Ab, the affinities were increased after immobilization. Although 
different values were estimated for affinity and capacity of immunoaffinity probes prepared 
with Abs from various suppliers, the probes with the same type of Abs performed similarly in 
terms of extraction of benzodiazepines from PBS buffer. All probes were found to exhibit 
higher capacities and lower affinities for oxazepam compared to the other two drugs. 
The probes prepared with highly cross-reactive Abs, as indicated by the suppliers, were 
found to have similar cross-reactivity for all three drugs while affinity purified fractions of 
Abs were slightly less cross-reactive towards diazepam and nordiazepam. A batch of probes 
that were prepared with oxazepam-specific Abs was found to have lower cross-reactivities for 
diazepam and nordiazepam. Thus, the oxazepam-specific probes can be successfully employed 
for extraction of oxazepam from samples that contain multiple drugs, without significant 
interference from diazepam and nordiazepam. In case of real samples, a variety of other 
molecules may be present that will compete for extraction with the analyte(s) of interest. Since 
such conditions are based on each individual sample, the cross-reactivity of probes for the 
potentially interfering compounds should be determined for each specific application. 
The extraction and desorption conditions were optimized for the probes. Extraction was 
performed for 45 minutes at 100 rpm while desorption was conducted in 15 minutes with 
agitation at 100 rpm. The probes were stored in PBS buffer containing 0.05% sodium azide at 
4
o
C, and were found to be stable with regard to extraction efficiency for three months 
following preparation.  
The applicability of various immunoaffinity probes for extraction of trace amounts of 
benzodiazepines from spiked plasma samples was demonstrated. In spite of their high 
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capacities and homogeneities, MAb probes were found to be ineffective for such applications. 
While performance of PAb probes in plasma samples were acceptable, affinity purified 
fractions of PAbs outperformed the other probes in extraction of benzodiazepines from 
plasma. Since MAb probes failed to adequately extract the benzodiazepines from plasma 
samples, affinity purification of PAbs was confirmed as a useful method for preparation of 
immunoaffinity probes to be used directly in biological matrices. The applicability of 
immunoaffinity SPME technique is extended by the use of PAbs for immunoaffinity probes 
because a wider variety of PAbs are commercially available and they are more cost-effective 
than MAbs.  
Non-specific binding was found to be insignificant in the range of concentrations used 
in this study. Excluding MAb probes, the method precision is below 10% for buffer and 
plasma extractions. The method’s LOD is 0.01 ng/mL and ULOQ is estimated to be 0.5 ng/mL 
and 2.0 ng/mL respectively. 
The pattern observed for Abs supplied by different companies was found to be similar 
in terms of affinity, homogeneity, capacity and cross-reactivity for the three benzodiazepines. 
This clearly demonstrates the usefulness of immunoaffinity SPME as a broadly applicable 
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